- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Myelofibrosis Graft versus host disease Polycythemia vera
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Ruxolitinib – March 2026
Tablet 5 mg, Tablet 10 mg, Tablet 15 mg, Tablet 20 mg
Last updated
11 March 2026